VIG vs XBI
Vanguard Dividend Appreciation ETF vs SPDR S&P Biotech ETF
- • VIG has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • VIG pays a higher dividend yield (1.51%).
Side-by-side metrics
| Metric | VIG | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.51% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $129.46B | $10.73B |
YTD return | 8.91% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.75 | 1.10 |
P/E ratio | 26.66 | — |
Last price | $238.89 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
VIG top holdings
| AVGO | Broadcom Inc | 5.39% |
| AAPL | Apple Inc | 4.55% |
| MSFT | Microsoft Corp | 4.26% |
| LLY | Eli Lilly and Co | 3.83% |
| JPM | JPMorgan Chase & Co | 3.31% |
| XOM | Exxon Mobil Corp | 2.66% |
| JNJ | Johnson & Johnson | 2.38% |
| V | Visa Inc Class A | 2.24% |
| WMT | Walmart Inc | 2.22% |
| CSCO | Cisco Systems Inc | 2.08% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About VIG
VIG (Vanguard Dividend Appreciation ETF) is US companies with a record of growing dividends. Managed by Vanguard, the fund carries $129.5B in assets under management, an expense ratio of 0.04%, a dividend yield of 1.51%. Its largest holding is Broadcom Inc (AVGO), which represents 5.4% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 4.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.